Bayer Corporate Newshttp://www.bayer.comThu, 20 Jun 2013 01:45:10 GMTBayer AG, Leverkusen, GermanyAll internationally relevant press releases from the Bayer Grouphttp://www.bayer.com/img/bayer-kreuz.gif Bayer Corporate Newshttp://www.bayer.com6767enPositive Phase 3 Results for VEGF Trap-Eye (Intravitreal Aflibercept) in Myopic Choroidal Neovascularization (mCNV) (for specialized target groups only)http://www.press.bayer.com/baynews/baynews.nsf/id/8CF2BE8BDEA90C07C1257B810051CA80http://www.press.bayer.com/baynews/baynews.nsf/id/8CF2BE8BDEA90C07C1257B810051CA80Thu, 06 Jun 2013 06:30:00 GMTBayer acquires majority interest in Conceptus http://www.press.bayer.com/baynews/baynews.nsf/id/FC8C4A1DB9314251C1257B81001CAFFChttp://www.press.bayer.com/baynews/baynews.nsf/id/FC8C4A1DB9314251C1257B81001CAFFCWed, 05 Jun 2013 06:30:00 GMT96.4 percent of Conceptus’ shares tendered / Conceptus imminently to become a wholly-owned Bayer subsidiaryPositive Phase III Data on Sorafenib Show Significant Improvement in Progression-Free Survival Time in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer (for specialized target groups only)http://www.press.bayer.com/baynews/baynews.nsf/id/FD1075BF48CE0B8BC1257B7C004958A5http://www.press.bayer.com/baynews/baynews.nsf/id/FD1075BF48CE0B8BC1257B7C004958A5Sun, 02 Jun 2013 11:30:00 GMTCurrently there are no approved therapies specifically for radioactive iodine refractory differentiated thyroid cancer / Sorafenib (Nexavar®) significantly extended progression-free survival; median progression-free survival of 10.8 months, compared to 5.8 months with placebo / Results from pivotal Phase III DECISION trial presented in plenary session at Annual Meeting of the American Society of Clinical OncologyAntitrust clearance obtained for Bayer's acquisition of Conceptus http://www.press.bayer.com/baynews/baynews.nsf/id/C9C3F70857DE5249C1257B7A001BCE1Dhttp://www.press.bayer.com/baynews/baynews.nsf/id/C9C3F70857DE5249C1257B7A001BCE1DWed, 29 May 2013 06:00:00 GMTOffer expires at midnight on June 4/5, 2013Bayer’s Xarelto® Approved in the EU for Secondary Prevention after an Acute Coronary Syndrome (for specialized target groups only)http://www.press.bayer.com/baynews/baynews.nsf/id/964F43B50C9B51C7C1257B7500494394http://www.press.bayer.com/baynews/baynews.nsf/id/964F43B50C9B51C7C1257B7500494394Fri, 24 May 2013 14:30:00 GMTFollowing an ACS event, one in ten patients will have another major atherothrombotic event (cardiovascular death, myocardial infarction or stroke) within a year / Xarelto 2.5 mg BID in combination with antiplatelet therapy can help prevent athero-thrombotic events by providing more complete protection than antiplatelet therapy alone / Xarelto is approved to protect patients from blood clots across more venous and arterial thromboembolic conditions than any other novel oral anticoagulant